AKT inhibitor Hu7691 induces differentiation of neuroblastoma cells.
10.1016/j.apsb.2023.01.024
- Author:
Shaowei BING
1
;
Senfeng XIANG
2
;
Zhimei XIA
2
;
Yilong WANG
1
;
Zhonghai GUAN
1
;
Jinxin CHE
2
;
Aixiao XU
2
;
Xiaowu DONG
2
;
Ji CAO
2
;
Bo YANG
2
;
Jinhu WANG
1
;
Qiaojun HE
2
;
Meidan YING
1
Author Information
1. Department of Surgical Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310052, China.
2. Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
- Publication Type:Journal Article
- Keywords:
AKT;
AKT inhibitor;
Differentiation therapy;
High-risk;
Neuroblastoma;
Target therapy
- From:
Acta Pharmaceutica Sinica B
2023;13(4):1522-1536
- CountryChina
- Language:English
-
Abstract:
While neuroblastoma accounts for 15% of childhood tumor-related deaths, treatments against neuroblastoma remain scarce and mainly consist of cytotoxic chemotherapeutic drugs. Currently, maintenance therapy of differentiation induction is the standard of care for neuroblastoma patients in clinical, especially high-risk patients. However, differentiation therapy is not used as a first-line treatment for neuroblastoma due to low efficacy, unclear mechanism, and few drug options. Through compound library screening, we accidently found the potential differentiation-inducing effect of AKT inhibitor Hu7691. The protein kinase B (AKT) pathway is an important signaling pathway for regulating tumorigenesis and neural differentiation, yet the relation between the AKT pathway and neuroblastoma differentiation remains unclear. Here, we reveal the anti-proliferation and neurogenesis effect of Hu7691 on multiple neuroblastoma cell lines. Further evidence including neurites outgrowth, cell cycle arrest, and differentiation mRNA marker clarified the differentiation-inducing effect of Hu7691. Meanwhile, with the introduction of other AKT inhibitors, it is now clear that multiple AKT inhibitors can induce neuroblastoma differentiation. Furthermore, silencing AKT was found to have the effect of inducing neuroblastoma differentiation. Finally, confirmation of the therapeutic effects of Hu7691 is dependent on inducing differentiation in vivo, suggesting that Hu7691 is a potential molecule against neuroblastoma. Through this study, we not only define the key role of AKT in the progression of neuroblastoma differentiation but also provide potential drugs and key targets for the application of differentiation therapies for neuroblastoma clinically.
